CDMOs offering Biologics Development & Manufacturing with Cell Therapy
10 published
10 published CDMOs match Biologics Development & Manufacturing and Cell Therapy.
Locations in this set include United States, Japan, China, Denmark, India, and United Kingdom.
Capabilities that show up most often in this set: CMC Analytical Development, Monoclonal Antibody (mAb) Manufacturing, Process Development, Recombinant Protein Manufacturing, and Technology Transfer.
Matching companies
AGC BiologicsGlobal CDMO offering development and manufacturing for protein expression biologics, pDNA, mRNA, viral vectors (AAV, LVV, RVV), and genetically engineered cells with scale-out manufacturing capabilities.
AsimovAsimov provides cell line development, upstream process development, and viral vector manufacturing services powered by proprietary synthetic biology platforms (CHO Edge, LV Edge, AAV Edge, RNA Edge) that deliver high-titer, stable cell lines and production systems for biologics, cell therapies, and gene therapies.
CatalentGlobal CDMO providing end-to-end contract development and manufacturing for pharma, biotech, and consumer health. Delivers 60+ billion doses annually across small molecules, biologics, cell & gene therapies, and clinical supply.
Charles River LaboratoriesCharles River Laboratories provides contract research, development, and manufacturing services across the full drug discovery and development continuum, supporting 80% of FDA-approved drugs over the past five years.
Dr. Reddy's LaboratoriesIntegrated global pharmaceutical company manufacturing generics, APIs, biosimilars, and innovative medicines across 66 countries with capabilities in small molecule and biologics development and manufacturing.
FUJIFILM BiotechnologiesCDMO partner offering end-to-end biologics development and manufacturing from pre-clinical through commercialization, with expertise in cell culture, microbial fermentation, cell and gene therapy, and cGMP manufacturing across US and European facilities.
Lonza Cell & Gene TechnologiesLonza is the world's leading CDMO, founded in Switzerland in 1897, serving the healthcare industry with integrated offerings for contract development and manufacturing of therapies across multiple modalities.
National ResilienceEnd-to-end CDMO specializing in complex modalities including cell, gene, and RNA-based therapies with North American manufacturing facilities and development capabilities.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Markdown mirror: /explore/biologics-development-manufacturing/cell-therapy.md